The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity : preliminary analysis of 1115 patients in the MRC AML15 Trial

1 Citations

Journal

  • Blood

    Blood 108 (11), 8a-, 2006

Citations (1)*help

See more

Details 詳細情報について

  • CRID
    1570009750995515904
  • NII Article ID
    10025193379
  • Data Source
    • CiNii Articles

Report a problem

Back to top